ERBB2 and gastric cancer: In the phase II DESTINY-Gastric01 study Trastuzumab Deruxtecan was compared with standard chemotherapy in HER2+ advanced gastric cancer patients having received at least two previous lines of therapy, including anti-HER2 treatment.